Cite
HARVARD Citation
Haas, N. et al. (2015). Phase I-II study of ADXS31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC): the KEYNOTE-046 trial. Journal for immunotherapy of cancer. 3 (2), pp. 1-2. [Online].